The development of highly selective, oral agents like Tyrosine Kinase Inhibitors (TKIs) has introduced crucial flexibility and improved efficacy for patients managing Her2-positive breast cancer. Unlike intravenous monoclonal antibodies which require infusion centers, oral drugs offer the convenience of at-home administration, significantly enhancing the patient's quality of life and reducing...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek